Quercetin as an Anticancer Agent: Focus on Esophageal Cancer by Davoodvandi, Amirhossein et al.
 
 
Quercetin as an Anticancer Agent: Focus 
on Esophageal Cancer 
 
Davoodvandi, A., Varkani, M. S., Clark, C. & Jafarnejad, S. 
 
Author post-print (accepted) deposited by Coventry University’s Repository 
 
Original citation & hyperlink:  
Davoodvandi, A, Varkani, MS, Clark, C & Jafarnejad, S 2020, 'Quercetin as an 
Anticancer Agent: Focus on Esophageal Cancer', Journal of Food Biochemistry, vol. 








This is the peer reviewed version of the following article: Davoodvandi, A, Varkani, 
MS, Clark, C & Jafarnejad, S 2020, 'Quercetin as an Anticancer Agent: Focus on 
Esophageal Cancer', Journal of Food Biochemistry, vol. 44, no. 9, e13374, which has 
been published in final form at https://dx.doi.org/10.1111/jfbc.13374. This article 
may be used for non-commercial purposes in accordance with Wiley Terms and 
Conditions for Self-Archiving. 
 
Copyright © and Moral Rights are retained by the author(s) and/ or other copyright 
owners. A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge. This item cannot be reproduced or quoted extensively 
from without first obtaining permission in writing from the copyright holder(s). The 
content must not be changed in any way or sold commercially in any format or medium 
without the formal permission of the copyright holders.  
 
This document is the author’s post-print version, incorporating any revisions agreed during 
the peer-review process. Some differences between the published version and this version 
may remain and you are advised to consult the published version if you wish to cite from 
it.  
 
Quercetin as an Anticancer Agent: Focus on Esophageal 
Cancer 
 
Amirhossein Davoodvandi1, 3, Mohammad Shabani Varkani1, Cain C. T. Clark2, 
and Sadegh Jafarnejad3 
1- Student Research Committee, Kashan University of Medical Sciences, Kashan, 
Iran 
2- Faculty of Health and Life Sciences, Coventry University, Coventry, United 
Kingdom 
3- Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
University of Medical Sciences, Kashan, I.R. Iran. 
 
 




* Corresponding Author. Research Center for Biochemistry and Nutrition in Metabolic 
Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran. Tel: +98-31-
55463378; Fax: +98-31-55463377. E-mail addresses: sjafarnejad@alumnus.tums.ac.ir 
Abstract 
Esophageal cancer (EC) is regarded as the sixth highest contributor to all cancer-related 
mortality, worldwide. In spite of advances in the treatment of EC, currently used methods 
remain ineffective. Quercetin, as a dietary anti-oxidant, is a plant flavonol from the 
flavonoid group of polyphenols, and can be found in numerous vegetables, fruits, and 
herbs. Quercetin can affect the processes of cancer-related diseases via cell proliferation 
inhibitory effects, potential apoptosis effects, and anti-oxidant properties. Of the various 
types of cancer, the use of quercetin has now become prominent in the treatment of EC . 
In this review, we discuss how quercetin may be an important supplement for the 
prevention, treatment, and management of EC, owing to its natural origin, and low-cost 
relative to synthetic cancer drugs. However, most findings cited in the current study are 
based on in vitro and in vivo studies, and thus, further human-based research is 
necessitated. 
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Practical Applications 
- In spite of advances in the treatment of esophageal cancer, currently used methods 
remain ineffective, therefore, an alternative or complementary therapy is required. 
- Quercetin, as a dietary anti-oxidant, can affect the processes of cancer-related 
diseases via cell proliferation inhibitory effects, potential pro-apoptotic functions, and 
anti-oxidant properties. 
- Quercetin may be an important supplement for the prevention, treatment, and 
management of EC, owing to its natural origin. 
-  The low cost of quercetin as supplement or dietary intake, relative to synthetic 
cancer drugs, is an advantage of the compound which should be considered. 
1. The epidemiology and pathophysiology of esophageal cancer 
Annually, more than 570,000 individuals are diagnosed with Esophageal cancer (EC), 
globally (Bray et al., 2018). EC is ranked as the sixth highest contributor to cancer-
related mortality worldwide, with over 500,000 deaths in 2018 (Bray et al., 2018). EC is 
classified into two types according to the type of cells that are involved in the cancer 
pathophysiology; Esophageal Adenocarcinoma (EAC) and Esophageal Squamous Cell 
Carcinoma (ESCC) (B. Gupta & Kumar, 2017), respectively. The epidemiology of EC is 
changing; indeed, ESCC was reported to be the most prevalent form of EC in the 
preceding four decades, whilst, presently, the incidence of EAC is rising rapidly in the 
United States and extended parts of Europe. Following these changes in the incidence of 
EC, among white males, EA has become the most prevalent type (H.-Z. Zhang, Jin, & 
Shen, 2012). Additionally, EAC is predominantly prevalent in Western countries, while 
ESCC is the prevailing form in the Middle East to the Northern regions of China, 
colloquially known as the "esophageal cancer belt" (Eslick, 2009).  
ESSC involves the squamous cells in the middle portion of the esophagus (Chen et al., 
2017). Tobacco and alcohol consumption are the main risk factors for the progression of 
ESCC (Pandeya, Olsen, & Whiteman, 2013). Nitrosamine and aldehyde levels are 
increased following tobacco use and alcohol consumption, respectively, and are 
considered as possible carcinogenic agents related to ESCC (Stoner, Wang, & Chen, 
2007). Furthermore, vitamin A, vitamin C, and trace elements deficiency are the major 
risk factors for the high prevalence of ESCC in "esophageal cancer belt" (Jessri, 
Rashidkhani, Hajizadeh, Jessri, & Gotay, 2011). Whilst in Western regions; Plummer-
Vinson Syndrome, hereditary tylosis, radiation history in thoracic parts, achalasia, weak 
oral hygiene, and poor economic status are the most prominent risk factors of ESCC (Dar 
et al., 2013).  
EAC affects the gastro-esophageal junction (GEJ) in the lower portion of the esophagus 
(Alexandre, Long, & Beales, 2014). Dysplasia, the abnormal growth of cells, occurs in 
the cells with the mucus production responsibility in the GEJ and consequently, EAC 
occurs in this region (Alexandre et al., 2014). The Gastro-esophageal junction 
adenocarcinoma is divided into three types, based on the distance of malignancies from 
the GEJ. Type I (tumors of the distal esophagus), type II (true cardiacarcinoma), and type 
III (subcardial gastric carcinoma) (Siewert & Stein, 1998). Barrett’s esophagus, tobacco 
smoking, inadequate consumption of fruits and vegetables, obesity (specially, central 
obesity), and subsequent gastro-esophageal reflux disease (GERD), are the potential risk 
factors for EAC (Veugelers, Porter, Guernsey, & Casson, 2006). Barrett’s esophagus is 
characterized by the switch between normal stratified squamous mucosa and glandular 
mucosa in the lining layer of lower esophagus (Fitzgerald, 2005); whilst chronic exposure 
of the epithelium to GERD is the main cause of Barrett’s esophagus induction 
(Malfertheiner & Hallerbäck, 2005). The incidence of GERD is increasing worldwide 
(Bevilacqua et al., 2018); moreover, one of the most prominent factors that has a 
significant effect on GERD causality, is obesity (El-Serag, 2008). Obesity  can cause 
intra-abdominal pressure on the stomach and, as a result, reflux. (Chang & Friedenberg, 
2014). In fact, a higher prevalence of obesity in Europe and US is asserted to have caused 
higher incidence of GERD and Barrett’s esophagus, and consequently, the prevalence of 
EAC has increased in these regions (Kubo & Corley, 2006). Previous studies have 
suggested that a history of the use of nonsteroidal anti-inflammatory drugs (NSAIDs) 
may decrease the risk of EAC (Khalaf, Nguyen, Ramsey, & El–Serag, 2014). In addition, 
previous infections with Helicobacter pylori in patients is associated with lower risk for 
the development of EAC (Anderson et al., 2008). Accordingly, lower acidity and reduced 
secretion of stomach are the possible mechanisms, following H.pylori infections,  for 
reducing GERD and EAC risk (Franceschi, Gasbarrini, Polyzos, & Kountouras, 2015). 
Moreover, it is conceivable that, due to health developments in Western populations, and 
lower prevalence of H.pylori infection, the incidence of EAC is increasing (Blaser, 2008). 
2. Latest and current management principles of EC: 
2.1. Endoscopic treatment  
Due to limited lymph node metastases, endoscopic mucosal resection (EMR) and 
endoscopic submucosal dissection (ESD) are the two most used treatment methods for 
early stage esophageal cancer (EEC) (Fujishiro, 2008). However, tumor characteristics, 
nodal (N) and metastatic (M) status, referred to as (TNM) staging, must be evaluated 
before endoscopic therapy (Pennathur, Gibson, Jobe, & Luketich, 2013). Endoscopic 
therapy is regarded the best method for patients with severe comorbidities or who do not 
wish to be a candidate for esophagectomy in muscularis mucosa (MM) or slightly 
submucosal invasive cancer (Isomoto, Yamaguchi, Minami, & Nakao, 2013). However, 
there are several complications related to EMR and ESD, including; pain, bleeding, and 
perforation, which may be caused by the application of  ESD (Isomoto et al., 2013). 
2.2. Surgical methods 
Open esophagectomy (OE): Surgical resection can be used as a specific treatment 
method. However, numerous empirical investigations have suggested that it may be 
better to use resection in combination with other methods, in a multimodal approach 
(Pennathur & Luketich, 2008). Surgical procedures, such as transhiatal esophagectomy 
(Kutup et al., 2014), Ivor Lewis esophagectomy (Xie et al., 2014), and three-incision 
modified McKeown esophagectomy (laparotomy, right thoracotomy and neck 
anastomosis), (J. Zhou et al., 2009) are examples of currently performed procedures. The 
use of each method depends on surgical preference and tumor volume; but the application 
of each approach must result in the complete removal of the tumor with dissection of 
impacted lymph nodes. Despite all of the advances in esophageal resection techniques, 
complications such as anastomotic leaks, fistula, postoperative pulmonary complications, 
and chylothorax can occur perioperatively (Grimminger et al., 2018). 
Minimally invasive esophagectomy (MIE): OE is associated with severe morbidity and 
mortality (Jamieson et al., 2004; Morita et al., 2008). Thus, to remedy such high mortality 
rates, a new surgical procedure was described in the 1990s (Hoppo, Jobe, & Hunter, 
2011; Yamamoto, Weber, Karl, & Meredith, 2013). In this procedure, thoracoscopic 
mobilization is used to avoid thoracotomy and laparotomy, and consequently, 
postoperative outcomes such as pulmonary infections are reduced (Palanivelu et al., 
2006). There are several approaches for MIE, such as total MIE (laparoscopic and 
thoracoscopic esophagectomy) (Watanabe, Baba, Nagai, & Baba, 2013) and hybrid MIE 
(thoracoscopy and laparotomy/laparoscopy and thoracotomy) (Mariette et al., 2019) 
which are intricate operations. However, the beneficial effects of MIE in treatment of EC 
is regarded as controversial (D’Journo & Thomas, 2014; Dhamija et al., 2013; Sarkaria & 
Rizk, 2014). Indeed, surgical treatments are invasive methods which are not preferred in 
all patients with cancer, primarily due to the limitation of surgical methods for metastatic 
lymph nodes (Collins et al., 2011). 
2.3. Non-surgical methods 
Neoadjuvant chemotherapy: is defined as the administration of complementary agents 
in EC patients, before the resection of the tumor (Y. Zhang et al., 2018). This procedure 
has a significant role in the improvement of operability, by shrinking the volume of 
tumor prior to surgery (Y. Zhang et al., 2018); moreover, radiological investigations can 
be incorporated for assessing pharmacological effects prior to the operation (Park et al., 
2016). However, previous history of cardiovascular diseases (CAD) and kidney disorders 
for systemic chemotherapy are regarded as contraindications (Huang et al., 2017). 
Interestingly, the most common procedure for the treatment of locally advanced 
esophageal carcinoma, tends to vary by country, for instance, Neoadjuvant 
chemoradiotherapy is regarded as the preferential treatment in the USA (van der Wilk et 
al., 2018).  
Definitive chemo-radiotherapy (CRT): Medicines commonly used in chemotherapy are 
5-Fluorouracil, Oxaliplatin, Epirubicin, Docetaxel, and Cisplatin (Al-Batran et al., 2017; 
Nishida et al., 2019; Sakai et al., 2019). For ESSC localized in the upper third of 
esophagus, is regarded as an optimal treatment method, whilst for localized ESSC in the 
middle or lower esophagus, CRT plus surgery may be the most beneficial procedure 
(Allum et al., 2011).  
Chemotherapy has numerous complications, such as immunosuppression and 
myelosuppression, reduction of  the hematocrit (thrombocytopenia, and anemia), 
lethargy, renal toxicity, nausea and vomiting, hair loss, secondary neoplasm, infertility, 
peripheral neuropathy, and cognitive disorders (Ades, Tryfonidis, & Zardavas, 2017; 
Pearce et al., 2017; Ramirez et al., 2009). Moreover, radiotherapy also has many adverse 
effects, for example, nausea and vomiting, injury of epithelial surfaces, gastrointestinal 
sores, inflammation, fibrosis, dryness, polyneuropathy, and lymphedema(Agarwal, 
Upadhyay, & Agarwal, 2012). 
Overall, the selection of the most efficient treatment method is dependent on the involved 
area, progression level of cancer, and the stage of the disease, whilst the clinical 
condition of the patients can also affect the selection of treatment method (Agarwal et al., 
2012; Cappelli, Shah, & Bingham, 2017; Collins et al., 2011; Newhauser, de Gonzalez, 
Schulte, & Lee, 2016; Pearce et al., 2017). Currently, despite advances in the treatment of 
EC, because of the numerous side effects and high cost attributed to novel procedures, 
current and pervasive methods remain ineffective. Thus, finding new procedures, 
alternative treatments, and complementary therapies is vital for individuals with EC, and 
especially in patients with EAC. 
3. Quercetin: a potential agent in cancer management 
Presently, the use of natural products and medicinal herbs in the treatment and 
management of health concerns has increased globally, particularly due to the minimal 
adverse effects, and significant therapeutic impacts these plants are reported to elicit. 
Previous studies have suggested that natural products can be used instead of, or 
concomitant to, present pharmacological treatments well, however, the efficacy of these 
alternative treatments should be evaluated (Firenzuoli, Gori, Crupi, & Neri, 2004; 
McCulloch et al., 2011). Numerous studies have shown that different medicinal herbs, 
such as Cinnamomum species, Curcuma species, Artemisia species, and their 
components, have a wide range of anticancer activities, such as apoptosis induction, 
angiogenesis inhibition, and cell growth inhibition (Bevara et al., 2018; Jung et al., 2018; 
Mayzlish-Gati et al., 2018; P. Zhou et al., 2019). These properties in the prevention of 
cancer development are related to the presence of various ingredients in vegetables, 
fruits, and medicinal herbs (R. K. Gupta, Soni, Shrivastava, Rajput, & Parashar, 2018). 
Flavonoids are polyphenolic phytochemicals found abundantly in different types of 
vegetables and fruits (Mazza, 2018). Flavonoids include; flavonols, flavones, flavanones, 
flavanols, anthocyanidins, and isoflavones, whilst the structural differences that exist in 
flavonoid molecules make their bioavailability exclusive (Cassidy et al., 2010; Ding et 
al., 2016; Gu et al., 2004). In different studies, numerous beneficial properties in 
flavonoid compounds have been reported, where consumption of these compounds 
purportedly reduces the risk of cancer, and chronic brain and heart disorders (Kozlowska 
& Szostak-Wegierek, 2014; Panche, Diwan, & Chandra, 2016).  
Quercetin (3, 3', 4', 5, 7-pentahydroxyflavone) is a flavonoid compound present in many 
fruits, vegetables, seeds, and medicinal plants, such as green tea (Iwashina, 2000; 
Schröder et al., 2019). Rich sources of quercetin include onions, apples, grapes, berries, 
broccoli, citrus fruits, tea, and capers (Bischoff, 2008; D'Andrea, 2015). All flavonoids 
(like quercetin) have a flavone nucleus that consists of two benzene rings linked together 
with a heterocyclic pyrone ring (T.-y. Wang, Li, & Bi, 2018). Aglycon and glycoside are 
two prevalent forms of quercetin that play critical roles in the metabolism of this 
compound (Erlund et al., 2000; Sahpazidou et al., 2014). Indeed, pprevious investigations 
have demonstrated that the biosynthesis of quercetin and other flavonoids is associated 
with defensive responses from the plants against environmental agents, including 
ultraviolet sunlight and lipid peroxidation (Mariani et al., 2008). Quercetin is insoluble in 
water and slightly soluble in alcohol (Li et al., 2009). The absorption of quercetin 
glycosides in the small intestine is relatively low, hence, the microflora in lower bowel 
hydrolyze the quercetin glycosides to quercetin and sugar, and this quercetin will be 
absorbed into the enterohepatic system (Buchweitz, Kroon, Rich, & Wilde, 2016). The 
antioxidant functions of quercetin confer beneficial impacts within the body, for instance, 
inhibitory properties of antioxidant compounds can reduce reactive oxygen species 
(ROS) (M. Zhang et al., 2011). Due to the high reactivity and instability of ROS, when in 
high abundance, this agent can cause various chronic disorders in different parts of the 
human body, including the endocrine system and cancer disturbance (Pham-Huy, He, & 
Pham-Huy, 2008). Given that quercetin contains high antioxidant capacity, it has been 
asserted that it may have a role in the prevention of cancers (Khansari, Shakiba, & 
Mahmoudi, 2009). The effects of quercetin on numerous types of cancers has been 
related to its capability in decreasing cancer cell growth, inhibition of angiogenesis, ROS 
induction in cancerous cells, and apoptosis induction (Igura, Ohta, Kuroda, & Kaji, 2001; 
Long et al., 2013).  
4. Molecular mechanisms uunderlying quercetin-mediated effects in 
cancer 
4.1. Effects on apoptosis induction 
Quercetin has a crucial role in the regulation and induction of apoptosis in cancer cells in 
vitro and in vivo, and has pro-apoptotic activity through the upregulation of the p53 gene 
and suppression of Bcl-2 protein. Moreover, following inhibition of transcription of Bcl-
2, the apoptosis process occurs in the cell and may inhibit the progression of tumors . In a 
study performed by Chien et al., increases in p53 expression levels, and mitochondrial 
and caspase-3-dependent pathways activation was observed in human breast cancer 
MDA-MB-231 cells, and consequently, apoptotic cell death occurred within cancer cells 
(Chien et al., 2009). In another study, upregulation of the expression of Bax and 
cytochrome c (Cyt-c) led to independent mitochondrial apoptosis in human gastric cancer 
cells (Shen et al., 2016). Indeed, a number of studies have demonstrated that quercetin 
may play a critical role in apoptosis process through expression of the p53 gene (Chan, 
Yang, Huang, Liao, & Yeh, 2013; G. T. Kim, Lee, Kim, & Kim, 2014; G. Wang, Zhang, 
Liu, Sharma, & Dong, 2012). Blueberry is regarded as one of the most abundant sources 
of quercetin and other flavonoids, such as kaempferol and gentisic acid (Shi, Loftus, 
McAinch, & Su, 2017). Sezar and colleagues evaluated the anti-cancer effects of 
different flavonoids extracted from blueberries in HCT-116 colon cancer cell line 
(Demirel Sezer et al., 2019); reporting that the inhibitors of apoptosis protein (IAPs) were 
inhibited at the end of study (Demirel Sezer et al., 2019). IAPs are a group of proteins 
reported to play a crucial role in the progression of different cancer types, especially in 
colorectal cancer (Miura et al., 2011). 
4.2. Effects on cell growth and proliferation 
Inhibition of the cell growth and proliferation may represent a further, distinct, 
mechanism capable of playing a critical role in the anti-cancer effects of quercetin. 
Sahpazidou and colleagues investigated the effects of green tea and its components, such 
as quercetin, on MCF‑7 and MDA-MB-231 breast carcinoma cell line, and reported that 
quercetin decreased the cell proliferation of cancer cells (Sahpazidou et al., 2014). In 
A375 malignant melanoma cell lines, quercetin inhibited the cell growth through 
downregulation of the Wnt/β-catenin signaling pathway (Srivastava & Srivastava, 2019). 
In another study, quercetin induced cell cycle arrest was found in the G1 phase, and was 
attributed to the downregulation of Cyclin B1 and cyclin-dependent kinase 1 (CDK1) and 
essential components of G2/M cell cycle progression (Jeong, An, Kwon, Rhee, & Lee, 
2009). Moreover, quercetin also inhibited cell growth in a dose-dependent manner on 
A375SM human melanoma cells, although conferred no significant effect on A375P 
human melanoma cell line. Additionally, in vivo treatment with quercetin (50 and 100 
mg/kg) significantly reduced tumor volume in comparison with a control group (S.-H. 
Kim et al., 2019).  
4.3. Effects on oxidative stress 
Reactive oxygen species accumulation is a biotic factor in the incidence of cancer, whilst 
inhibiting oxidative stress plays an important role in preventing cancer in normal cells 
(Lesjak et al., 2018; Rezaei-Sadabady, Eidi, Zarghami, & Barzegar, 2016). In the human 
body, Granulosa Cells (GCs) are one of the most sensitive cells to ROS (Rashidi et al., 
2019). Indeed, Rashidi et al (Rashidi et al., 2019) demonstrated that Quercetin is capable 
of upregulating the expressions of the antioxidant response element (ARE) pathway, 
nuclear factor (erythroid-derived 2)-like 2 (Nrf2) gene and thioredoxin (Trx) system in 
hydrogen peroxide (H2O2)-treated GCs. In HT29 and HCT15 human colon cancer cell 
lines, quercetin may be able to induce ROS generation in cancer cells, eventually leading 
to apoptosis (Priyadarsini & Nagini, 2012); indeed, in vivo and in vitro work has 
demonstrated  destruction of cancer cells following quercetin introduction (Fonseca-
Silva, Inacio, Canto-Cavalheiro, & Almeida-Amaral, 2011; Lee, Hwang, Kwon, Surh, & 
Park, 2010; H. Zhang et al., 2012). The treatment of MCF-7 cancer cell lines with 
quercetin, quercetin-3′-sulfate, and quercetin-3-glucuronide, respectively, has been 
shown to lead to the generation of intracellular ROS in these cells (Wu et al., 2018). High 
ROS production in the body has been associated with some inflammatory mediators, such 
as cyclooxygenase 2 (COX-2) (Onodera, Teramura, Takehara, Shigi, & Fukuda, 2015); 
indeed, in HT29 human colon cancer cells, 40 μM of quercetin significantly upregulated 
the levels of COX-2 as a ROS mediator (Raja et al., 2017). 
5. Quercetin-mediated effects in EC 
The anti-cancer effects of quercetin, alone (Q), or as a complementary therapy with 
butyrate (Q+B), in human esophageal 9706 cancer cells has previously been evaluated, 
with the authors reporting that treatment by Q, B, or both, downregulated the expression 
of the DNA Methyltransferase 1 (DNMT1), NF-κBp65, Histone deacetylase 1 (HDAC1), 
Cyclin D1, and upregulated the expression of caspase-3 and cyclin-dependent kinase 
inhibitor 2A (p16INK4α) levels in Eca9706 cells compared with control (C). Furthermore, 
following these alterations, the growth and proliferation of cancer cells was inhibited in 
Q, B ,and Q+B, in comparison with the C; whilst it was also documented that the 
concomitant effects of Q+B were stronger than Q or B alone (Zheng, Wang, Yang, & 
Wu, 2014).  
Cancer stem cells (CSCs) are one of the most potent agents in the progression of tumors 
and metastases (Nassar & Blanpain, 2016). Chemo/radiation therapy resistance of these 
cells is associated with cancer relapse after treatment (Batlle & Clevers, 2017; Nishikawa 
et al., 2013). CD133 (prominin-1) is a biomarker of CSCs in colorectal cancers (Ren, 
Sheng, & Du, 2013). The effects of nanoliposomal quercetin (nLQ) alone, and liposomal 
quercetin (LQ) in combination with CD133 anti-serum, was investigated in human ESCC 
and Eca-109/9706 cancer stem cells (CSCs) (Zheng, Mo, Li, & Wu, 2014). Accordingly, 
treatment with nLQ decreased the levels of NF-κBp65, HDAC1, and cyclin D1, and 
increased the expression of caspase-3. Consequently, apoptosis occurred in the 
Eca109/9706 cells and the cell growth was inhibited; however, in the combination group, 
the apoptotic effects were greater than nLQ alone, suggesting that quercetin, as a 
complementary therapy, is more potent than a specific treatment method (Zheng, Mo, et 
al., 2014).  
The potential anti-cancer effects of flavonols has always been regarded as controversial. 
Indeed,  flavonols (quercetin, kaempferol, myricetin) and flavones (luteolin, apigenin, 
chrysin) were shown to elicit cell cycle arrest in the G2/M phase following the 
upregulation of p21 and downregulation of cyclin B1 in human esophageal squamous cell 
carcinoma cell line KYSE-510. Furthermore, increases in the levels of PIG3 and cleavage 
of caspase-9 and caspase-3 resulted in apoptosis in cancer cells; however, thee effects 
quercetin and luteolin was greater than other phytochemicals used (Q. Zhang, Zhao, & 
Wang, 2009). Similarly, Zhang and colleagues demonstrated that the use of quercetin, 
and other flavonols (quercetin, kaempferol, myricetin) and flavones (luteolin, apigenin, 
chrysin), has an apoptotic effect on the upregulation of PIG3 and cleavage of caspase-3, -
9, and a cell growth inhibitory effect, via up-regulation of GADD45b and 14-3-3σ, and 
down-regulation of cyclin B1 in a human esophageal adenocarcinoma cell line (OE33) 
(Q. Zhang, Zhao, & Wang, 2008). Furthermore, Zhang et al reported the cytotoxicity 
effects of quercetin were more powerful than other components, and that treatment of 
cancer cells by quercetin, increased the expression of p18 as a cyclin-dependent kinase 
inhibitor that plays a critical role in the inhibition of cell growth via inducing cell cycle 
arrest (Q. Zhang, Zhao, & Wang, 2008).  
5‑fluorouracil (5‑FU) is commonly used in the chemotherapy of EC; although, because of 
the low efficacy of 5‑FU, it is administrated in combination with other medicines (Shim 
et al., 2010). However, chemotherapy activates the Nuclear factor- kappaβ (NF‑κB) 
pathway that inhibits the anti-cancer effects of drugs used to treat EC due to its anti-
apoptotic and metastatic effects (Cusack et al., 2001; Voboril et al., 2004; C.-Y. Wang, 
Mayo, & Baldwin, 1996). Therefore, the use of some herbal adjuvants is suggested to 
increase the efficacy of chemotherapy in the treatment of EC, and attenuating possible 
chemoresistance. Chuang-xin et al. investigated the effects of quercetin, 5‑FU, and a 
combination of these two components, on the EC9706 and Eca109 cell lines. 
Accordingly, the treatment of cancer cells with quercetin, 5-FU, and a combination of 
quercetin and 5-FU, caused apoptosis in cells; however, in the combination treatment, 
because of the inhibitory effects of quercetin on NF‑κB activation pathway, the apoptotic 
effects on cancer cells was greater than two other treatments (Chuang‑Xin, Wen‑Yu, 
Yao, Xiao‑Yan, & Yun, 2012).  
The epidermal growth factor receptor (EGFR) activates downstream pathways such as 
phosphoinositide3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) and 
ERKs; these two pathways are regarded as critical in the initiation and progression of 
tumors (Samatar & Poulikakos, 2014). Quercetin-3-methyl ether (Q3ME) is one of the 
analogs of quercetin, and can inhibit the activation of AKT and ERKs. Moreover, 
activating protein-1 (AP-1) may be suppressed as a result of treatment by Q3ME in 
esophageal preneoplastic lesions, and can suppress cell growth and inflammation levels, 
in vivo (Zhao et al., 2018).  
6. Conclusion 
The incidence of EC is increasing worldwide; however, this type of cancer is still 
associated with high mortality and morbidity, which may be due to a lack of optimally 
effective treatments. Presently, natural products are utilized for the treatment or 
management of numerous disorders, because these plants confer minimal adverse side 
effects and have a high treatment potential. Quercetin is a flavonoid found in a number of 
vegetables, fruits ,and herbs, such as green tea, and may be useful alone or in 
combination with other methods for the treatment of EC. Quercetin has numerous anti-
esophageal cancer activities; however,, the pro-apoptotic activities of quercetin in the 
management of EC is not yet fully understood. In the present review, it was evident that 
quercetin appears to have greater effects when utilized concomitant to other treatment 
methods In this review, we discussed how quercetin may be an efficacious supplement 
for the prevention, treatment, and management of EC, owing to its natural origin and low 
cost, relative to synthetic cancer drugs. However, the evidence discussed in the current 
study is based on in vitro and in vivo experiments, and there exists little evidence 
regarding the impact of quercetin on human EC, and, thus, this represents a pragmatic 
avenue for further research. 
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